Akèy › Kansè ovè › Pennsylvania › Philadelphia

Etid klinik pou Kansè ovè nan Philadelphia, PA

44 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Ap rekriteFaz 2/3

Thomas Jefferson University Hospital, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Ap rekriteFaz 2

Pennsylvania Hospital, Philadelphia
Thomas Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
ak 4 plis

Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Ap rekriteFaz 1/2

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ap rekriteFaz 1

Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia

Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ap rekrite

University of Pennsylvania, Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05287451

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Ap rekriteFaz 2

University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ap rekriteFaz 2

Site 0232 - University of Pennsylvania, Philadelphia
Site 0178 - Thomas Jefferson University, Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825

Study of AVZO-021 in Patients With Advanced Solid Tumors

Ap rekriteFaz 1/2

Avenzo Therapeutics Recruiting Site, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251

DESTINY-PANTUMOUR04

Ap rekriteEtid obsèvasyon

Research Site, Philadelphia

Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Ap rekriteFaz 1/2

Perelman School of Medicine at the University of Pennsylvania, Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 24, 2026 · NCT04590326

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ap rekriteFaz 3

University of Pennsylvania Hospital, Philadelphia
Jefferson Health Honickman Center, Philadelphia
Asplundh Cancer Pavilion, Willow Grove · 13 mi lwen

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Ap rekriteFaz 1

University of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ap rekriteFaz 2

Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845

Prehabilitation in High-risk Oncologic Surgery

Ap rekrite

Fox Chase Cancer Center - Philadelphia, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07638410

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Ap rekriteFaz 1/2

University of Pennsylvania, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT04752826

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ap rekriteFaz 3

Hospital of the University of Pennsylvania ( Site 0071), Philadelphia

Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ap rekriteFaz 3

Lankenau Medical Center, Wynnewood · 7 mi lwen

Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Ap rekriteEtid obsèvasyon

University of Pennsylvania, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Ap rekriteFaz 1

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07216105

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ap rekriteFaz 1/2

Children's Hospital of Philadelphia, Philadelphia

12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Ap rekriteFaz 1

Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Ap rekriteFaz 1

SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07470853

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Ap rekriteFaz 1

Normunity Investigational Site, Philadelphia
Normunity Investigational Site, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

Ap rekriteEtid obsèvasyon

ACPMP, Springfield · 8 mi lwen

Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT07769346

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Ap rekriteFaz 3

Site 0109, Philadelphia
Site 0113, Philadelphia
Site 0114, Willow Grove · 13 mi lwen

Laj 18 ak plis · Fanm · Mizajou Aug 12, 2026 · NCT07546500

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ap rekrite

University of Pennsylvania/Abramson Cancer Center, Philadelphia
Fox Chase Cancer Center, Philadelphia
Lankenau Medical Center, Wynnewood · 7 mi lwen
ak 5 plis

Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ap rekriteFaz 3

University of Pennsylvania/Abramson Cancer Center, Philadelphia
Pennsylvania Hospital, Philadelphia
Thomas Jefferson University Hospital, Philadelphia
ak 5 plis

Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1/2

University of Pennsylvania / Abramson Cancer Center, Philadelphia
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia

Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068